Shopping Cart
- Remove All
Your shopping cart is currently empty
AXL-IN-14
😃Good
Catalog No. T73310Cas No. 2947506-65-0
AXL-IN-14 is a potent, orally active inhibitor of AXL with an IC50 of 0.8 nM that effectively suppresses Gas6/AXL-mediated cell migration and invasion, reduces the expression of p-AXL and p-AKT proteins, and demonstrates anti-tumor activity [1].
AXL-IN-14
😃Good
Catalog No. T73310Cas No. 2947506-65-0
AXL-IN-14 is a potent, orally active inhibitor of AXL with an IC50 of 0.8 nM that effectively suppresses Gas6/AXL-mediated cell migration and invasion, reduces the expression of p-AXL and p-AKT proteins, and demonstrates anti-tumor activity [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,820 | 8-10 weeks | |
| 50 mg | $2,380 | 8-10 weeks | |
| 100 mg | $3,100 | 8-10 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "AXL-IN-14"
Gilteritinib
Cited
ASP2215
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
- $34
Size
QTY
CitedCabozantinib S-malate
XL184, Cabozantinib Malate, Cabozantinib
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
- $40
Size
QTY
UNC2025
UNC-2025, UNC 2025, mrx-6313
T70071429881-91-3
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
- $33
Size
QTY
Sitravatinib Cited
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedNCT-503 Cited
NCT 503
T42131916571-90-8
NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=2.5 µM) with no activity against other dehydrogenases. NCT-503 has antitumor activity and inhibits the growth of PHGDH-dependent tumors.
- $35
Size
QTY
CitedBMS 777607
BMS-777607, BMS777607, BMS 817378
T26991025720-94-8
BMS 777607 (BMS 817378) is a Met-related inhibitor targeting c-Met, Axl, Ron, and Tyro3 with IC50 values of 3.9 nM, 1.1 nM, 1.8 nM, and 4.3 nM, respectively. BMS-777607 has been investigated in basic science research for malignant solid tumors.
- $30
Size
QTY
Cabozantinib Cited
XL184, BMS-907351
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
- $39
Size
QTY
CitedBemcentinib
Cited
R428, BGB324
T62691037624-75-1
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
- $34
Size
QTY
CitedDubermatinib
TP0903
T20051341200-45-0
Dubermatinib (TP0903) is a potent and selective Axl kinase inhibitor.
- $30
Size
QTY
G-749
G749, Denfivontinib
T26201457983-28-6
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
- $40
Size
QTY
AXL-IN-13
T733002376928-82-2In house
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM. It exhibits anticancer activity, reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
- $79
Size
QTY
Tepotinib Cited
MSC2156119, EMD-1214063
T61211100598-32-0
Tepotinib (EMD-1214063) is a c-MET tyrosine kinase inhibitor (IC50=3 nM) that is selective, orally active, and ATP-competitive. Tepotinib has antitumor effect and is used in the treatment of non-small cell lung cancer.
- $43
Size
QTY
CitedContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | AXL-IN-14 is a potent, orally active inhibitor of AXL with an IC50 of 0.8 nM that effectively suppresses Gas6/AXL-mediated cell migration and invasion, reduces the expression of p-AXL and p-AKT proteins, and demonstrates anti-tumor activity [1]. |
| In vitro | AXL-IN-14, at concentrations of 0.2, 1, and 5 nM for 1 hour, demonstrated a dose-dependent decrease in the expression levels of p-AXL and p-AKT proteins [1]. With a 72-hour exposure, AXL-IN-14 exhibited antiproliferative activity, achieving an IC50 value of 21.8 nM in EBC-1 cells [1]. Additionally, AXL-IN-14, at 20 and 100 nM for 24 hours, inhibited Gas6/AXL-mediated cell migration and invasion in H1299 and SNU449 cells [1]. |
| In vivo | AXL-IN-14 (1, 10 mg/kg; p.o.; once daily for 11 days) exhibited antitumor activity in nude mice [1]. |
| Molecular Weight | 566.55 |
| Formula | C32H24F2N4O4 |
| Cas No. | 2947506-65-0 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy AXL-IN-14 | purchase AXL-IN-14 | AXL-IN-14 cost | order AXL-IN-14 | AXL-IN-14 chemical structure | AXL-IN-14 in vivo | AXL-IN-14 in vitro | AXL-IN-14 formula | AXL-IN-14 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.